SLFN11 and small cell lung carcinoma: SCLC-A cell lines with high expression of SLFN11 are more resistant to cisplatin, whereas SLFN11 low expression was accompanied by increased sensitivity to cisplatin [63], suggesting a potential clinical biomarker.